Silence raises $50m+ to pursue 'better understood' RNAi drugs
This article was originally published in Scrip
Executive Summary
London, UK-based Silence Therapeutics has raised a total of £38.9m ($58.2m) to fund development of its pipeline of RNA interference (RNAi) therapeutics.